Data Shows What You Already Know: U.S. Health Care Is Bleak

A West Health–Gallup survey of roughly 20,000 U.S. adults (June–August) finds pronounced and worsening affordability, access and racial disparities in American health care: 30% of households skipped recommended care due to cost, 55% experienced long appointment waits, and 9% said they knew someone who died after not getting treatment (vs. 5% in 2022). Major drops in perceived access among Black (−13 pts to 41%) and Hispanic (−17 pts to 34%) respondents contrast with steady White responses (58%); 47% now fear they won’t be able to afford necessary care next year. The results, paired with upcoming political fights over ACA subsidy extensions and looming Medicaid work requirements, heighten policy risk for insurers, providers and regional health markets and could drive voter-focused reforms.

Analysis

Market structure: Persistent affordability gaps (30% skipped care; 20% unable to afford prescriptions; 47% worried about future care) shift pricing power toward payers/PBMs and low‑cost providers (retail clinics, generics, telehealth). Winners: UNH/CVS/CI and large retail (WMT, WBA) that can scale low‑cost dispensing; losers: hospital operators and elective‑dependent device makers (HCA, MDT, SYK) facing volume and margin pressure, especially in high‑skip states where elective volumes could be 20–40% depressed versus low‑skip states.

Risk assessment: Key tail risks include a failure to extend ACA subsidies (30–90 day policy window) raising uninsured rates and muni hospital credit stress, or a political push for price controls that would hurt pharma margins. Immediate (days) reaction centers on legislative signaling; short term (3–12 months) earnings volatility for payers/hospitals; long term (1–3 years) structural shift to retail/telehealth and consolidation. Hidden drivers: workforce shortages, state Medicaid policy (work requirements in 2027) and telehealth reimbursement rules.

Trade implications: Favor payer/PBM and retail clinic long exposure and selective short hospital/exposure to elective devices. Use defined‑risk option structures into policy events (30–90 days) and position sizes of 1–3% NAV per idea, trimming on defined thresholds (e.g., +15% on longs, −10% on shorts). Monitor subsidy vote, CMS guidance, and state Medicaid actions as catalysts.

Contrarian angles: Consensus may over‑discount elective backlog rebound — delayed care can create pent‑up demand that benefits hospitals/devices once subsidies or consumer confidence improve; however, a political pivot to price controls would flip winners to losers. Use pairs and option hedges to express this binary outcome rather than outright directional exposure.

Key Decisions for Investors

• Establish a 2.5% NAV long in UnitedHealth (UNH) over 6–12 months; rationale: market share gains from expanded on‑exchange enrollment if subsidies extended and lower uncompensated care; exit/trim on +15% or after subsidy resolution within 90 days.
• Open a 1.5% NAV short in HCA Healthcare (HCA) for 3–6 months, expressing elective volume risk; hedge with a 6‑month HCA call spread (buy 1.5% NAV 5% OTM calls, sell 0.75% NAV 10% OTM) to cap upside; cover if HCA falls ≥10% or if state-level indicators show <10% drop in elective scheduling.
• Buy a 6‑9 month call spread on CVS Health (CVS) (size 1% NAV): buy slightly OTM calls (+3–7% strike), sell higher strike to fund; thesis: PBM/retail clinic and dispensing volume rise if affordability pressures push consumers to lower‑cost channels; unwind post legislative clarity (30–90 days after vote).
• Initiate a pair trade: long Walmart (WMT) 1% NAV / short Medtronic (MDT) 1% NAV for 6 months to capture rotation to retail low‑cost care vs elective device weakness; rebalance if hospitalization utilization metrics reverse by >5% month‑over‑month.
• Avoid municipal hospital credit exposure and underweight taxable muni hospital bonds by 50% vs benchmark until ACA subsidy outcome is resolved or hospital uncompensated care metrics improve; re‑assess after 90 days or on credit downgrades.